Increasingly, manufacturers want standard facility designs of their GMP manufacturing facilities so they can be replicated elsewhere in the world, but this approach comes with unique considerations.
Read More
In-house production vs. CDMO: meeting the challenges of commercializing cell and gene therapies
Commercializing cell and gene therapies efficiently requires timely decisions about whether to engage a CDMO or develop internal manufacturing capacity. Sometimes the best solution is to do both.
Read More
The dynamic future of life-saving medicine
Changing the way therapies work, and the changing work of making therapies.
Read More
Fill-finish in ATMP: 5 critical questions to ask on the way to process scale-up
To bring the exciting science of cell and gene therapy manufacturing to life, creating smaller-scale filling solutions is imperative to the success of the ATMP industry. But before you begin scaling your operation, there are important questions to consider about fill-finish in ATMP.
Read More
Zero carbon considerations for biotech facilities and operations
Your life sciences company can strive for zero carbon on your next project. Here’s how.
Read More
Partnering for speed: when global expertise meets local knowledge
Embracing the notion of a hybrid partner will support Europe-based life science innovators in delivering drug therapies faster and more cost-effectively.
Read More
An introduction to ATMP manufacturing
The facts, the challenges, and the way forward.
Read More
4 interior design trends bringing life to cell and gene facilities
The cell and gene industry is a competitive, exciting field that is centered on rapidly evolving science. It’s a vibrant world with unlimited possibilities—and with clever interior design, its facilities can reflect that same energy.
Read More
Designing multimodal GMP suites
Considerations for dedicated and campaigned use
Read More
5 current trends that will shape the life sciences in 2021 and beyond
Many of the life sciences trends that are driving innovation today were here pre-COVID, but the pandemic was an accelerant. For all that it took, it gave life science researchers and developers new momentum, and from that momentum, hope.
Read More